Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 24288157)

1.

Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators.

Bunch TJ, Anderson JL.

Am J Cardiovasc Drugs. 2014 Apr;14(2):89-100. doi: 10.1007/s40256-013-0056-x. Review.

PMID:
24288157
2.

Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.

Bollmann A, Husser D, Cannom DS.

Am J Cardiovasc Drugs. 2005;5(6):371-8. Review.

PMID:
16259525
3.
4.

Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.

Das MK, Zipes DP.

J Cardiovasc Pharmacol. 2010 May;55(5):438-49. Review.

PMID:
20509177
5.

Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.

Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD.

J Cardiovasc Electrophysiol. 2012 Mar;23(3):296-301. doi: 10.1111/j.1540-8167.2011.02183.x. Epub 2011 Sep 28.

PMID:
21955243
6.
7.

Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.

Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators.

JAMA. 2006 Jan 11;295(2):165-71.

PMID:
16403928
8.

Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.

Bunch TJ, Mahapatra S, Murdock D, Molden J, Weiss JP, May HT, Bair TL, Mader KM, Crandall BG, Day JD, Osborn JS, Muhlestein JB, Lappe DL, Anderson JL.

Pacing Clin Electrophysiol. 2011 Dec;34(12):1600-6. doi: 10.1111/j.1540-8159.2011.03208.x. Epub 2011 Sep 3.

PMID:
21895727
9.

Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?

Block M, Hammel D, Böcker D, Borggrefe M, Breithardt G.

Am J Cardiol. 1996 Sep 12;78(5A):62-8. Review.

PMID:
8820838
10.

A benefit-risk assessment of class III antiarrhythmic agents.

Elming H, Brendorp B, Pehrson S, Pedersen OD, Køber L, Torp-Petersen C.

Expert Opin Drug Saf. 2004 Nov;3(6):559-77. Review.

PMID:
15500415
11.

Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy.

Droogan C, Patel C, Yan GX, Kowey PR.

Heart Fail Clin. 2011 Apr;7(2):195-205, viii. doi: 10.1016/j.hfc.2010.12.003. Review.

PMID:
21439498
12.

Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.

Kowey PR, Crijns HJ, Aliot EM, Capucci A, Kulakowski P, Radzik D, Roy D, Connolly SJ, Hohnloser SH; ALPHEE Study Investigators.

Circulation. 2011 Dec 13;124(24):2649-60. doi: 10.1161/CIRCULATIONAHA.111.072561. Epub 2011 Nov 14.

13.

Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches.

Borne RT, Varosy PD, Masoudi FA.

JAMA Intern Med. 2013 May 27;173(10):859-65. doi: 10.1001/jamainternmed.2013.428. Review.

PMID:
23546173
14.
15.

Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.

Ho AT, Pai SM, Timothy P, Pai RG.

Pacing Clin Electrophysiol. 2005 Jul;28(7):647-53.

PMID:
16008799
16.

Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.

Haverkamp W, Eckardt L, Borggrefe M, Breithardt G.

Am J Cardiol. 1997 Oct 23;80(8A):67G-73G. Review.

PMID:
9354413
17.

Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.

Gali WL, Sarabanda AV, Baggio JM, Ferreira LG, Gomes GG, Marin-Neto JA, Junqueira LF.

Europace. 2014 May;16(5):674-80. doi: 10.1093/europace/eut422. Epub 2014 Jan 30.

18.

Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1.

19.

Antiarrhythmic drugs and ventricular defibrillation energy requirements.

Qi X, Dorian P.

Chin Med J (Engl). 1999 Dec;112(12):1147-52. Review.

PMID:
11721458
20.

Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators.

Lee CH, Nam GB, Park HG, Kim HY, Park KM, Kim J, Choi KJ, Kim YH.

Circ J. 2008 Jan;72(1):102-5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk